Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
All subjects with the study will be children (age 6-12) with Attention Deficit Hyperactivity
Disorder (ADHD). After baseline assessment confirms the presence of ADHD, children will have
an Event related potential (ERP) (a type of electroencephalogram [EEG]) study. After the
baseline EEG, children will be randomized to either placebo or GXR for a 4-week, parallel
groups trial. During this trial, dosing will be flexibly adjusted according to patient
response or presence of side effects. The dosage will range from 1-4 mg. At the end of the
four week trial, a follow up ERP study will be obtained.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio